Investing.comDoubao · 实盘不做把握 6/10不做原因:无增量信息
北京时间·🕒 发布 19:12:37·⟳ 抓取 19:13:24 +47s·⚡ 决策 10-19 19:18:42 +5m18s·8.2 天前
Zipalertinib 脑转移队列更新数据（颅内ORR 30.2%）将于 ESMO 2026 公布，但系同队列一年前数据的更新且弱于竞品
本次新闻稿是 REZILIENT2 同一脑转移队列在 ESMO 2025（2025-10-12 首发）之后的更新展示，核心疗效数字（30.2% 颅内 ORR）无质变且显著弱于竞品 sunvozertinib（约48% 颅内 ORR），不构成新的审批、注册终点或最佳同类证据；盘前仅+3.2% 且成交量约101股，无定价证据，做多无正期望；但数据本身并非负面意外（耐受性良好、NDA 在审），亦不满足做空红线。
📄 原文Investing.com↗ 原文
Zipalertinib shows 30% response rate in lung cancer brain metastases
PRINCETON, N.J. & CAMBRIDGE, Mass. - Taiho Oncology, Inc. and Cullinan Therapeutics, Inc. (NASDAQ:CGEM) announced resul…
不做 Cullinan Therapeutics（CGEM.US）
本次为 REZILIENT2 同一脑转移队列（2025-10 ESMO 已首发）的更新展示，30.2% 颅内 ORR 无质变且弱于竞品 sunvozertinib 约48%，无新审批/终点事件，正 edge 不足；同时数据并非负面意外且 PDUFA 催化临近，不满足做空红线。盘前+3.2% 仅约101股、不可作为定价依据，正式开盘前不挂单。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Zipalertinib 脑转移更新数据（iORR 30.2%）本质是一年前 ESMO 2025 已首发同队列数据的再展示，疗效数值弱于竞品 sunvozertinib（约48%），对 CGEM 无增量催化；盘前反应微小且流动性近乎为零，方向不明，不做。
消息传播链
- ESMO 2026 展示前一周发布的 Cohort C 更新数据：43 例可评估、颅内 ORR 30.2%；正式口头报告为 2026-10-26市场反应:CGEM 盘前 13.35 美元、+3.2%，但仅约101股成交，参考意义弱
关键理由
- 同一 CNS 队列已于 2025-10 在 ESMO 2025 发布，本次仅为更长随访的更新数据，预期差有限
- 30.2% 颅内 ORR 对比 sunvozertinib 脑转移约48% ORR 不具竞争力，不支持 best-in-class 重估
主要风险
- zipalertinib NDA 审批决议临近，若 ESMO 全文含更优亚组或监管利好，可能独立于本次数据推动股价，回避将踏空该催化
- 小盘临床期生物科技股盘前流动性极差，正式开盘后价格反应可能与盘前+3% 明显不同
反向证据
- 做多前查反向 · 来源 web · 日期 2025-10-13 · 影响 weakens
同一 CNS 队列一年前已首发，增量信息有限
检索:zipalertinib ESMO 2025 brain metastases intracranial ORR prior disclosure 原文 ↗ - 做多前查反向 · 来源 web · 影响 weakens
竞品颅内 ORR 约48%，本次30.2%不具竞争力，削弱 best-in-class 叙事
检索:sunvozertinib intracranial ORR brain metastases 48% competitor comparison 原文 ↗ - 做空前查反向 · 来源 web · 日期 2026-10-01 · 影响 invalidates
NDA 在审、突破性疗法认定、一线 III 期数据入选主席研讨会，存在临近正面催化，数据本身也并非负面意外
检索:Cullinan zipalertinib NDA approval breakthrough therapy REZILIENT3 positive 原文 ↗
先例如何影响了这次决策
对本次决策的影响:未改变结论——AVOID 基于 NO_INCREMENTAL_FACT，即使无先例也成立
方向:未构建先例面板：本结论不依赖事件后涨幅，而依赖数据增量缺失与竞争劣势
涨幅量级:无高相似对齐先例校准幅度
形态:未评估
工具执行结果 · 成功 9 · 降级 0 · 失败 1 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 12 ms
{"result": "search_processed_events:agent query=`cullinan therapeutics cgem zipalertinib esmo 2026 brain metastases | taiho zipalertinib egfr exon 20 insertion cns data | zipalertinib rezilient2 cohort c intracranial response`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent qu - web_search 成功 doubao_search · 1,873 ms
豆包搜索结果（原始查询:zipalertinib REZILIENT2 Cohort C intracranial ORR EGFR exon 20 insertion CNS metastases 2026；API SearchType:web） - web_search 成功 doubao_search · 1,907 ms
豆包搜索结果（原始查询:Cullinan Therapeutics Taiho zipalertinib royalties milestones deal terms CLN-081 revenue；API SearchType:web） - web_search 成功 doubao_search · 1,997 ms
豆包搜索结果（原始查询:sunvozertinib intracranial ORR brain metastases EGFR exon20 insertion vs zipalertinib competitor；API SearchType:web） - stock_quote 成功 stock_tools HTTP · 2,275 ms
{ - kb_search 失败 stock_tools HTTP · 57 ms
kb_search 服务暂不可用；这不是一条知识库命中。 - web_search 成功 doubao_search · 1,955 ms
豆包搜索结果（原始查询:zipalertinib ESMO 2025 brain metastases intracranial ORR REZILIENT2 Cohort C results October 2025；API SearchType:web） - web_search 成功 doubao_search · 1,492 ms
豆包搜索结果（原始查询:Cullinan Therapeutics CGEM stock drop September 2026 zipalertinib FDA advisory committee；API SearchType:web） - web_search 成功 doubao_search · 1,667 ms
豆包搜索结果（原始查询:zipalertinib PDUFA date approval timeline NDA EGFR exon 20 2026 Cullinan Taiho；API SearchType:web） - web_search 成功 doubao_search · 2,213 ms
豆包搜索结果（原始查询:"zipalertinib" ESMO 2025 "intracranial" response rate evaluable patients REZILIENT2 CNS cohort percent；API SearchType:web）
原文全文
展开原文 · 1,831 字
PRINCETON, N.J. & CAMBRIDGE, Mass. - Taiho Oncology, Inc. and Cullinan Therapeutics, Inc. (NASDAQ:CGEM) announced results from Cohort C of the Phase 2 REZILIENT2 trial evaluating zipalertinib in patients with non-small cell lung cancer harboring EGFR exon 20 insertion mutations or other uncommon EGFR mutations with active central nervous system metastases, according to a press release statement.
The data will be presented at the European Society for Medical Oncology Congress 2026 on October 26 in Madrid, Spain.
Among 43 evaluable patients, zipalertinib achieved an intracranial objective response rate of 30.2% and an intracranial disease control rate of 72.1%, with a median intracranial duration of response of 9.7 months. Among 24 patients without prior EGFR tyrosine kinase inhibitor exposure, the intracranial objective response rate was 37.5%.
At the data cutoff, 59 patients were enrolled, with a median follow-up of 9.2 months. Among the 43 evaluable patients, 29 had EGFR exon 20 insertion mutations. The median number of prior lines of therapy was two, and 19 patients had received prior EGFR tyrosine kinase inhibitor therapy.
Zipalertinib 100 mg twice daily was well tolerated. Common treatment-related adverse events included paronychia at 32.6% and diarrhea at 25.6%. Grade 3 or higher treatment-related adverse events occurred in 9 patients, or 20.9%.
Zipalertinib is an orally available small molecule designed to target activating mutations in EGFR and is being developed by Taiho Oncology, Taiho Pharmaceutical Co., Ltd., and Cullinan Therapeutics. The drug is investigational and has not been approved by any health authority.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Zipalertinib shows 30% response rate in lung cancer brain metastases
The data will be presented at the European Society for Medical Oncology Congress 2026 on October 26 in Madrid, Spain.
Among 43 evaluable patients, zipalertinib achieved an intracranial objective response rate of 30.2% and an intracranial disease control rate of 72.1%, with a median intracranial duration of response of 9.7 months. Among 24 patients without prior EGFR tyrosine kinase inhibitor exposure, the intracranial objective response rate was 37.5%.
At the data cutoff, 59 patients were enrolled, with a median follow-up of 9.2 months. Among the 43 evaluable patients, 29 had EGFR exon 20 insertion mutations. The median number of prior lines of therapy was two, and 19 patients had received prior EGFR tyrosine kinase inhibitor therapy.
Zipalertinib 100 mg twice daily was well tolerated. Common treatment-related adverse events included paronychia at 32.6% and diarrhea at 25.6%. Grade 3 or higher treatment-related adverse events occurred in 9 patients, or 20.9%.
Zipalertinib is an orally available small molecule designed to target activating mutations in EGFR and is being developed by Taiho Oncology, Taiho Pharmaceutical Co., Ltd., and Cullinan Therapeutics. The drug is investigational and has not been approved by any health authority.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Zipalertinib shows 30% response rate in lung cancer brain metastases
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
3082eb465e· 2026-10-19 19:18 · doubao / doubao-seed-evolving-latest-version · 策略包658c0c1e2ba5当前